Shanghai Labway Clinical Laboratory Co., Ltd. (301060.SZ)
CNY 10.3
(-0.77%)
CNY 10.3
(-0.77%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 546.98 Million | 84.16 Million | 223.51 Million | 167.87 Million | 70.6 Million | 184.79 Million |
| Net Income | -161.7 Million | 739.05 Million | 261.61 Million | 134.48 Million | 94.61 Million | 73.93 Million |
| Depreciation & Amortization | 65.36 Million | 78.24 Million | 59.34 Million | 43.69 Million | 47.85 Million | 40.35 Million |
| Deferred income taxes | -18.71 Million | -16.73 Million | 677.62 Thousand | -4.13 Million | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 452.41 Million | -983.47 Million | -123.54 Million | -29.47 Million | -99.09 Million | 47.88 Million |
| Other non-cash items | 26.82 Million | 250.34 Million | 26.09 Million | 19.18 Million | 27.23 Million | 22.62 Million |
| Investing Cash Flow | -398.49 Million | 180.05 Million | -403.4 Million | 83.72 Million | 77.49 Million | -83.63 Million |
| Investments in PPE | -398.88 Million | -230.07 Million | -118.88 Million | -44.54 Million | -39.51 Million | -73.34 Million |
| Acquisitions | -11.1 Million | 1917.46 | 13.48 Million | 52.5 Million | -1 Million | 635.92 Thousand |
| Investment purchases | -240.42 Million | -305.21 Million | -941 Million | -439.32 Million | -600.77 Million | -1.43 Billion |
| Sales/Maturities of investments | 247.91 Million | 710.66 Million | 650.98 Million | 559.63 Million | 702.93 Million | 1.41 Billion |
| Other Investing Activities | 11.48 Million | 4.67 Million | -7.99 Million | -44.54 Million | 15.84 Million | 4.41 Million |
| Financing Cash Flow | 44.72 Million | 50.48 Million | 119.75 Million | -96.11 Million | -96.4 Million | -35.29 Million |
| Debt repayment | -199.98 Million | -17.99 Million | -2 Million | - | -30 Million | -95 Million |
| Dividends payments | -129.95 Million | -125.61 Million | -302.42 Thousand | -35.24 Million | -64.41 Million | -3.47 Million |
| Common Stock Repurchased | -10.25 Million | - | - | - | - | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -18.54 Million | 194.09 Million | 122.05 Million | -60.84 Million | -1.98 Million | 63.17 Million |
| Accounts receivables | 1.06 Billion | -1.52 Billion | -298.02 Million | -82.46 Million | -57.51 Million | -35.37 Million |
| Accounts payables | -604.36 Million | 828.74 Million | 173.11 Million | 35.18 Million | 57.51 Million | - |
| Inventory | 14.83 Million | -273.17 Million | 690.33 Thousand | 21.93 Million | 2.27 Million | 8.17 Million |
| Other working capital | 5.08 Million | -16.73 Million | 677.62 Thousand | -4.13 Million | -101.36 Million | 39.7 Million |
| Cash at beginning of period | 665.62 Million | 351.47 Million | 411.59 Million | 256.35 Million | 205.19 Million | 139.94 Million |
| Cash at end of period | 858.27 Million | 665.62 Million | 351.47 Million | 411.59 Million | 256.35 Million | 205.19 Million |
| Capital Expenditure | -398.88 Million | -230.07 Million | -118.88 Million | -44.54 Million | -39.51 Million | -73.34 Million |
| Effect of forex changes on cash | -569.95 Thousand | -556.49 Thousand | 19.55 Thousand | -239.24 Thousand | -533.05 Thousand | -609.68 Thousand |
| Net cash flow / Change in cash | 192.64 Million | 314.14 Million | -60.12 Million | 155.24 Million | 51.15 Million | 65.25 Million |
| Free Cash Flow | 148.1 Million | -145.91 Million | 104.62 Million | 123.32 Million | 31.08 Million | 111.45 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -56.18 Million | 14.52 Million | 1.07 Million | -140.71 Million | -161.7 Million | 942.55 Thousand |
| Depreciation & Amortization | - | 23.96 Million | 23.96 Million | 65.36 Million | 65.36 Million | -27.85 Million |
| Deferred income taxes | - | - | - | - | -18.71 Million | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | - | - | 1.08 Billion | 452.41 Million | -554.16 Million |
| Other non-cash items | 76.18 Million | 314.54 Thousand | -39.8 Million | -714.13 Million | 26.82 Million | 698.39 Million |
| Investing Cash Flow | -14.04 Million | -16.93 Million | -17.45 Million | 57.11 Million | -398.49 Million | -419.96 Million |
| Investments in PPE | -15.9 Million | -18.19 Million | -17.65 Million | -46.64 Million | -398.88 Million | -320.12 Million |
| Acquisitions | 1.86 Million | 5.26 Million | 3.02 Million | 6.03 Million | -11.1 Million | 1.62 Million |
| Investment purchases | -30 Million | -94 Million | -50 Million | -100.42 Million | -240.42 Million | -140 Million |
| Sales/Maturities of investments | 30 Million | 90 Million | 50.16 Million | 200.4 Million | 247.91 Million | 40.12 Million |
| Other Investing Activities | - | 2.96 Million | 195.67 Thousand | 103.76 Million | 11.48 Million | -1.6 Million |
| Financing Cash Flow | -45.78 Million | -40.05 Million | -14.14 Million | -45.29 Million | 44.72 Million | 102.52 Million |
| Debt repayment | -37.5 Million | -20.96 Million | -5 Million | -30.18 Million | -199.98 Million | -25.46 Million |
| Dividends payments | - | -10.06 Million | -3.99 Million | -129.95 Million | -129.95 Million | -68.63 Million |
| Common Stock Repurchased | 9.14 Million | -9.14 Million | - | -10.25 Million | -10.25 Million | - |
| Common Stock Issuance | - | - | - | - | - | - |
| Other Financing Activities | -17.42 Million | -1.92 Million | -5.13 Million | -12.98 Million | -18.54 Million | 196.62 Million |
| Accounts receivables | - | - | - | 1.06 Billion | 1.06 Billion | -503.74 Million |
| Accounts payables | - | - | - | - | -604.36 Million | - |
| Inventory | - | - | - | 14.83 Million | 14.83 Million | -50.42 Million |
| Other working capital | - | - | - | 5.08 Million | 5.08 Million | - |
| Cash at beginning of period | 723.52 Million | 789.75 Million | 858.27 Million | 555.77 Million | 665.62 Million | 756.04 Million |
| Cash at end of period | 684.82 Million | 723.52 Million | 787.76 Million | 858.27 Million | 858.27 Million | 555.77 Million |
| Capital Expenditure | -15.9 Million | -18.19 Million | -17.65 Million | -46.64 Million | -398.88 Million | -320.12 Million |
| Effect of forex changes on cash | - | -514.24 Thousand | -165.52 Thousand | -424.03 Thousand | -569.95 Thousand | -135.48 Thousand |
| Net cash flow / Change in cash | -38.7 Million | -66.22 Million | -70.5 Million | 302.49 Million | 192.64 Million | -200.26 Million |
| Free Cash Flow | 4.09 Million | -27.32 Million | -56.39 Million | 244.44 Million | 148.1 Million | -202.8 Million |
603010
NYR
CWP
4456
HLEGLAS
SVAV